Abstract:Purpose In this preliminary study, we are aiming to develop a deep learning model to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) patient based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Background Neoadjuvant chemotherapy (NAC) has become a grown treatment method for patients with triple-negative breast cancer (TNBC). However, not every patient can achieve pathological complete response (pCR) to NAC. NAC also has side effects such as nausea, hair loss, appetite loss, mouth sores, and nerve damage. Additionally, delaying surgery to remove the tumor can allow it to spread, making treatment more difficult. Therefore, it is necessary to predict pCR to NAC reliably in a non-invasive way. Deep learning methods, especially convolutional neural network (CNN), have been shown great success in image-based treatment response prediction. Methods In this preliminary study, totally 78 TNBC patients on DCE-MRI collected from public dataset (Duke University) were used, among which are 23 patients with pCR and 55 patients without pCR. For each patient, the median slice from the tumor area of the fat-saturated gradient echo T1-weighted pre-contrast sequence MRI was extracted. A convolutional neural network model was built to predict whether the patients receive pCR or not after NAC. In the constructed prediction model, three convolutional layers were used to capture the features from DCE-MRI. Each convolutional layer was followed by a max-pooling layer to reduce the dimensions of the feature maps. Two fully connected layers were added into the model so that the model has a binary outcome which provides the prediction of pCR. Additionally, "ReLU" was used as the activation function in all the layers except for the output layer which used "softmax" instead. By using augmentation technique, we solved the problems of small sample size and unbalance data. Results In this study, 75% dataset were used for training and the remaining 25% were used for testing. The model we developed has a 75% accuracy, with a sensitivity of 0.67 and a specificity of 0.79. These results indicate that the model performs well in predicting patients who do not achieve pathological complete response (pCR). Additionally, the area under the receiver operating characteristic (AUC) curve is calculated as 0.74, indicating the outstanding performance. Citation Format: Xi Chen, Zhiguo Zhou. A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2) nr B038.

Prediction of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer by using a deep learning model with 18F-FDG PET/CT

Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using a Deep Learning (DL) Method

Deep learning-based predictive model for pathological complete response to neoadjuvant chemotherapy in breast cancer from biopsy pathological images: a multicenter study

The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer

Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer

Deep Learning-Based Predictive Biomarker of Pathological Complete Response to Neoadjuvant Chemotherapy from Histological Images in Breast Cancer

Deep learning-based prediction of response to HER2-targeted neoadjuvant chemotherapy from pre-treatment dynamic breast MRI: A multi-institutional validation study

Deep Learning Model for Predicting the Pathological Complete Response to Neoadjuvant Chemoradiotherapy of Locally Advanced Rectal Cancer

Cross-modal deep learning model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer

Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI

Abstract B038: A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer

Deep Learning Radiomic Analysis of DCE-MRI Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Deep Learning Prediction of Pathologic Complete Response in Breast Cancer Using MRI and Other Clinical Data: A Systematic Review

Prediction of therapy response of breast cancer patients with machine learning based on clinical data and imaging data derived from breast [18F]FDG-PET/MRI

Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study

18 F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients

Deep learning radiomic analysis of DCE-MRI combined with clinical characteristics predicts pathological complete response to neoadjuvant chemotherapy in breast cancer

Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach

Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer

18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis.

A hierarchical self-attention-guided deep learning framework to predict breast cancer response to chemotherapy using pre-treatment tumor biopsies